Sale speculation: We assess German Merck's biosimilar business
Germany’s Merck has refused to comment on rumours it is looking to sell its biosimilars business, but what would a hypothetical buyer actually get?
Archives for November 4, 2016
Shire closing US plant as it begins to assess post-Baxalta manufacturing footprint
Shire says it is closing a plasma fractionating facility in Los Angeles, US but remains positive it can successfully manage its post-Baxalta manufacturing network of 17 sites.
Biocon Malaysia insulin plant set to supply Lantus biosimilar under EU review
Biocon says it is well-positioned to up production of its Lantus biosimilar after the insulin glargine – co-developed with Mylan – was accepted for review in the EU.
Biologics manufacturing services boost for Charles River Labs in Q3
Biologics manufacturing and testing activities helped Charles River Laboratories grow in Q3 and will drive further gains say analysts.